H.R. 1066 (114th): Clinical Trials Modernization Act of 2015

To amend the Federal Food, Drug, and Cosmetic Act to promote the use of adaptive trial designs, Bayesian methods, and other innovative statistical methods in clinical protocols for drugs, biological products, and devices, and with respect to the requirement to conduct postapproval studies and clinical trials, and for other purposes.

The bill’s titles are written by its sponsor.



Feb 25, 2015
114th Congress, 2015–2017

Died in a previous Congress

This bill was introduced on February 25, 2015, in a previous session of Congress, but was not enacted.


Chris Collins

Representative for New York's 27th congressional district



Read Text »
Last Updated: Feb 25, 2015
Length: 7 pages


Feb 25, 2015

This is the first step in the legislative process.

H.R. 1066 (114th) was a bill in the United States Congress.

A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.

This bill was introduced in the 114th Congress, which met from Jan 6, 2015 to Jan 3, 2017. Legislation not enacted by the end of a Congress is cleared from the books.

How to cite this information.

We recommend the following MLA-formatted citation when using the information you see here in academic work:

“H.R. 1066 — 114th Congress: Clinical Trials Modernization Act of 2015.” www.GovTrack.us. 2015. April 25, 2017 <https://www.govtrack.us/congress/bills/114/hr1066>

Where is this information from?

GovTrack automatically collects legislative information from a variety of governmental and non-governmental sources. This page is sourced primarily from Congress.gov, the official portal of the United States Congress. Congress.gov is generally updated one day after events occur, and so legislative activity shown here may be one day behind. Data via the congress project.